Top View
- Anti-IL6R: Tocilizumab, Satralizumab, Sarilumab, Olokizumab, Vobarilizumab Anti-IL6: Siltuximab, Sirukumab, Clazakizumab
- Journal for Immunotherapy of Cancer (JITC) Preprint
- Antibody Modeling
- International Nonproprietary Names (INN) for Biological and Biotechnological Substances
- Certolizumab Pegol for Treating Rheumatoid Arthritis Following
- Spotlight on Sirukumab for the Treatment of Rheumatoid Arthritis: the Evidence to Date
- (12) United States Patent (10) Patent No.: US 9.295,731 B2 Nguyen (45) Date of Patent: Mar
- Translating IL-6 Biology Into Effective Treatments
- Kinase Inhibition in Autoimmunity and Inflammation
- Supplementary Tables and Figures Section 1. Distribution of CDR-H3
- Covid-19 and Patients Undergoing Pharmacological Treatments for Immune-Mediated Inflammatory Diseases: Protocol for a Rapid Living Systematic Review
- Interleukin-6 As a Therapeutic Target Jean-Francois¸ Rossi1,2,3, Zhao-Yang Lu4, Michel Jourdan2, and Bernard Klein2,3
- A Novel Small-Molecule Inhibitor Targeting the IL-6 Receptor B Subunit, Glycoprotein 130
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Covid-19 and Patients Undergoing Pharmacological Treatments for Immune-Mediated Inflammatory Diseases: Protocol for a Rapid Living Systematic Review
- Joint-Specific DNA Methylation and Transcriptome Signatures In
- Effect of Medicine on Interleukin-6 Inhibitors and Their Forms Against COVID-19
- ( 12 ) Patent Application Publication ( 10 ) Pub . No .: US 2020/0405883 A1 BILIC Et Al
- IL-6 Targeting Compared to TNF Targeting in Rheumatoid Arthritis: Studies of Olokizumab, Sarilumab and Sirukumab
- Esophagitis: Drugs Picture of Iron Pill Material in Biopsy TT’S Kodachrome 1St Page Folder Iron Medication Injury Medications/Drugs
- A Pharmacological Interactome Between COVID-19 Patient Samples and Human Sensory Neurons Reveals Potential Drivers of Neurogenic
- (INN) for Biological and Biotechnological Substances
- Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment
- Is IL-6 a Key Cytokine Target for Therapy in COVID-19?
- Antibodies[Version 1; Peer Review: 2 Approved]
- Quintiles Ph II-III Clinical Protocol
- Janssen Research & Development Briefing Document Arthritis Advisory
- WO 2018/039557 Al 01 March 2018 (01.03.2018) W !P O PCT
- Cytokine Targeting in Rheumatoid Arthritis T ⁎ Viet L
- Compounds and Methods for Treating Inflammatory
- L 2018 Conference Needs Assessment
- Interleukin-6 in Rheumatoid Arthritis
- International Nonproprietary Names (INN) for Biological and Biotechnological Substances
- Pbr Excluded Drugs List
- COVID-19 and Patients with Immune-Mediated Inflammatory
- Quantify RA Clinical Outcomes Database
- Analysis of Mirna Expression in Patients with Rheumatoid Arthritis During Olokizumab Treatment
- Efficacy of Pharmacological Treatment in Rheumatoid Arthritis
- Antibodies to Watch in 2018